---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-005316"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2026-08-06T20:01:21+00:00"
generated_at: "2026-08-06T20:02:28.520001+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Celldex Q2 net loss $73.5M; barzolvolimab Phase 3 CSU topline data expected Sept/Oct 2026

## Summary
- Net loss of $73.5M ($0.94/share) vs $56.6M in Q2 2025; no material revenue.
- Cash $717.6M after $323.8M public offering; runway through 2028.
- Barzolvolimab Phase 3 CSU enrolled 1,939 patients; topline data Sept/Oct 2026; BLA planned 2027.
- Phase 2 prurigo nodularis study failed primary endpoints; discontinued.
- CDX-622 Phase 1 showed rapid tryptase reduction; asthma POM study ongoing; expanding into allergic rhinitis and food allergy.

## SEC filing metadata
- accession: 0001171843-26-005316
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2026-08-06T20:01:21+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184326005316/0001171843-26-005316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184326005316/f8k_080626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-005316
- JSON: https://secwatch.observer/filing/0001171843-26-005316.json
- Plain text: https://secwatch.observer/filing/0001171843-26-005316.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.